Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 11/20 | 0.58 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2400725 | 1.00 | FFAR2 (0.58) | FFAR2UCHL1USP30NPC1RAB9A | |
| SCHEMBL1916532 | 0.94 | FFAR2 (0.59) | FFAR2UCHL1USP30NPC1RAB9A | |
| SCHEMBL1916536 | 0.94 | FFAR2 (0.59) | FFAR2UCHL1USP30NPC1RAB9A | |
| SCHEMBL2399167 | 0.94 | FFAR2 (0.57) | FFAR2UCHL1USP30NPC1RAB9A | |
| SCHEMBL2399171 | 0.94 | FFAR2 (0.57) | FFAR2UCHL1USP30NPC1RAB9A | |
| SCHEMBL2399421 | 0.93 | FFAR2 (0.54) | FFAR2GRM1 | |
| SCHEMBL2399425 | 0.93 | FFAR2 (0.54) | FFAR2GRM1 | |
| SCHEMBL2052730 | 0.92 | FFAR2 (0.62) | FFAR2UCHL1USP30NPC1RAB9A | |
| SCHEMBL2052731 | 0.92 | FFAR2 (0.62) | FFAR2UCHL1USP30NPC1RAB9A | |
| SCHEMBL2398004 | 0.92 | FFAR2 (0.58) | FFAR2CNR1TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-09-22 | — | — | US | claimed |
| EP-2364297-A1 | Compounds, pharmaceutical composition and methods for use in treating metabolic disorders | Euroscreen S.A. (BE) | 2011-09-14 | — | — | EP | claimed |
| WO-2010066682-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2010-06-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | CPT1A, LIPC, PC | FFAR2 295/4885UCHL1 3346/4885USP30 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.